Buchumschlag

Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma: a retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Information regarding the curative role of allogeneic stem cell transplantation (allo-HCT) in systemic anaplastic large cell lymphoma (sALCL) is scarce. We analyzed the results of allo-HCT in patients with relapsed/refractory sALCL with special emphasis on the role of brentuximab vedotin (BV) as a b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Domingo-Domènech, Eva (VerfasserIn) , Boumendil, A. (VerfasserIn) , Climent, F. (VerfasserIn) , Socié, G. (VerfasserIn) , Kroschinsky, F. (VerfasserIn) , Finel, H. (VerfasserIn) , Vandenbergue, E. (VerfasserIn) , Nemet, D. (VerfasserIn) , Stelljes, M. (VerfasserIn) , Bittenbring, J. T. (VerfasserIn) , Robinson, S. (VerfasserIn) , Montoto, S. (VerfasserIn) , Sureda, A. (VerfasserIn) , Dreger, Peter (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: [2020]
In: Bone marrow transplantation
Year: 2019, Jahrgang: 55, Heft: 3, Pages: 633-640
ISSN:1476-5365
DOI:10.1038/s41409-019-0732-9
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41409-019-0732-9
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41409-019-0732-9
Volltext
Verfasserangaben:E. Domingo-Domènech, A. Boumendil, F. Climent, G. Socié, F. Kroschinsky, H. Finel, E. Vandenbergue, D. Nemet, M. Stelljes, J.T. Bittenbring, S. Robinson, S. Montoto, A. Sureda, P. Dreger on behalf of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Beschreibung
Zusammenfassung:Information regarding the curative role of allogeneic stem cell transplantation (allo-HCT) in systemic anaplastic large cell lymphoma (sALCL) is scarce. We analyzed the results of allo-HCT in patients with relapsed/refractory sALCL with special emphasis on the role of brentuximab vedotin (BV) as a bridge to allo-HCT. Forty-four patients (24 females, median age 38 years) with sALCL were included. Twenty-three patients (52%) received BV before allo-HCT; BV-treated patients were more heavily pretreated (≥3 lines of therapy in 74% vs. 38%, p = 0.04). Twenty-three patients (52%) were in complete remission (CR) at allo-HCT. Three-year nonrelapse mortality and incidence of relapse (IR) after allo-HCT were 7% and 40%, respectively. With a median follow-up of 39 (12-69) months for survivors, 3-year progression-free survival (PFS) and overall survival were 53% and 74%, respectively. Univariate analysis showed that heavily pretreated patients and those not in CR had a higher IR and a lower PFS. The use of BV before transplant did not impact on any of the outcomes. Allo-HCT is a curative therapeutic strategy in a significant proportion of patients with relapsed/refractory sALCL; BV does not seem to modify transplant-related outcomes but might be able to render more patients candidates for this curative treatment.
Beschreibung:Published online: 6 November 2019
Gesehen am 16.04.2020
Beschreibung:Online Resource
ISSN:1476-5365
DOI:10.1038/s41409-019-0732-9

Ähnliche Einträge